Literature DB >> 11274765

Low-intensity conditioning is sufficient to ensure engraftment in matched unrelated bone marrow transplantation.

A Nagler1, M Aker, R Or, E Naparstek, G Varadi, C Brautbar, S Slavin.   

Abstract

OBJECTIVE: Matched unrelated bone marrow transplantation (BMT) for patients with hematological malignancies is associated with a high incidence of transplant-related complications due to high doses of chemoradiotherapy administered pre-BMT to ensure engraftment. The aim of this study was to investigate the feasibility of low-intensity conditioning for BMT from matched unrelated donors.
MATERIALS AND METHODS: Sixteen patients with hematologic malignancies underwent non-T-cell-depleted BMT following a low-intensity conditioning regimen consisting of fludarabine monophosphate 30 mg/m(2)/day for 6 days, busulfan 4 mg/kg/day for 2 days, anti-T lymphocyte globulin 10 mg/kg/day for 4 days. Seven of the patients suffered from chronic myelogenous leukemia, four from acute lymphoblastic leukemia, four from acute myelogenous leukemia, and one from Ki-1 non-Hodgkin's lymphoma. Three of the patients had secondary leukemia and two were post-autologous BMT (ABMT). All patients were transplanted from fully matched unrelated donors.
RESULTS: Fifteen of the 16 patients had 100% donor chimerism; no graft rejection was observed. None of the patients developed >Grade II veno-occlusive disease, sepsis, multiorgan failure, or renal or pulmonary toxicity. Four patients died posttransplant; one of thrombocytopenia and severe hemorrhagic cystitis, one of central nervous system toxicity, one of Grade IV graft-vs-host disease, and one following relapse (9 months post-BMT). Survival and disease-free survival at 36 months are 75% (95% confidence interval 46-90%) and 60% (95% confidence interval 30-80%), respectively.
CONCLUSION: These results indicate that low-intensity conditioning is sufficient to ensure stable engraftment of bone marrow grafts in a matched unrelated setting.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11274765     DOI: 10.1016/s0301-472x(00)00655-x

Source DB:  PubMed          Journal:  Exp Hematol        ISSN: 0301-472X            Impact factor:   3.084


  16 in total

1.  A prospective multicenter study of unrelated bone marrow transplants using a reduced-intensity conditioning regimen with low-dose ATG-F.

Authors:  S Fuji; S W Kim; S Yano; S Hagiwara; H Nakamae; M Hidaka; T Ito; K Ohashi; K Hatanaka; A Takami; S Kurosawa; T Yamashita; T Yamaguchi; T Fukuda
Journal:  Bone Marrow Transplant       Date:  2015-11-09       Impact factor: 5.483

Review 2.  Hematologic aspects of myeloablative therapy and bone marrow transplantation.

Authors:  Roger S Riley; Michael Idowu; Alden Chesney; Shawn Zhao; John McCarty; Lawrence S Lamb; Jonathan M Ben-Ezra
Journal:  J Clin Lab Anal       Date:  2005       Impact factor: 2.352

3.  Expansion of donor-reactive host T cells in primary graft failure after allogeneic hematopoietic SCT following reduced-intensity conditioning.

Authors:  M Koyama; D Hashimoto; K Nagafuji; T Eto; Y Ohno; K Aoyama; H Iwasaki; T Miyamoto; G R Hill; K Akashi; T Teshima
Journal:  Bone Marrow Transplant       Date:  2013-09-09       Impact factor: 5.483

Review 4.  Hematopoietic cell transplantation as a form of immunotherapy.

Authors:  Frederick R Appelbaum
Journal:  Int J Hematol       Date:  2002-04       Impact factor: 2.490

5.  Reduced-intensity conditioning regimen with low-dose ATG-F for unrelated bone marrow transplant is associated with lower non-relapse mortality than a regimen with low-dose TBI: a single-center retrospective analysis of 103 cases.

Authors:  Shigeo Fuji; Niina Ueno; Nobuhiro Hiramoto; Yoshitaka Asakura; Kimikazu Yakushijin; Yutaro Kamiyama; Saiko Kurosawa; Sung-Won Kim; Yuji Heike; Takuya Yamashita; Takahiro Fukuda
Journal:  Int J Hematol       Date:  2013-10-04       Impact factor: 2.490

6.  Unrelated-donor bone marrow transplantation with a conditioning regimen including fludarabine, busulfan, and 4 Gy total body irradiation.

Authors:  Yasushi Onishi; Shin-ichiro Mori; Shigeru Kusumoto; Kyoko Sugimoto; Daigo Akahane; Yuriko Morita-Hoshi; Sung-Won Kim; Takahiro Fukuda; Yuji Heike; Ryuji Tanosaki; Kensei Tobinai; Yoichi Takaue
Journal:  Int J Hematol       Date:  2007-04       Impact factor: 2.490

Review 7.  The transplantation of hematopoietic stem cells after non-myeloablative conditioning: a cellular therapeutic approach to hematologic and genetic diseases.

Authors:  Michael Maris; Rainer Storb
Journal:  Immunol Res       Date:  2003       Impact factor: 2.829

8.  Reduced-intensity unrelated donor bone marrow transplantation for hematologic malignancies.

Authors:  Sung-Won Kim; Keitaro Matsuo; Takahiro Fukuda; Masamichi Hara; Kosei Matsue; Shuichi Taniguchi; Tetsuya Eto; Mitsune Tanimoto; Atsushi Wake; Kazuo Hatanaka; Shinji Nakao; Yoji Ishida; Mine Harada; Atae Utsunomiya; Masahiro Imamura; Yoshinobu Kanda; Kazutaka Sunami; Fumio Kawano; Yoichi Takaue; Takanori Teshima
Journal:  Int J Hematol       Date:  2008-09-17       Impact factor: 2.490

Review 9.  Graft-versus-host disease, the graft-versus-leukemia effect, and mixed chimerism following nonmyeloablative stem cell transplantation.

Authors:  Shimon Slavin
Journal:  Int J Hematol       Date:  2003-10       Impact factor: 2.490

Review 10.  New strategies for prevention and treatment of graft-versus-host disease and for induction of graft-versus-leukemia effects.

Authors:  H Joachim Deeg
Journal:  Int J Hematol       Date:  2003-01       Impact factor: 2.490

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.